PolyPid Ltd.

PYPD

IL0011326795

Pharmaceuticals

Delayed Nasdaq Other stock markets 12:46:37 2024-05-09 EDT			5-day change	1st Jan Change
4.5 ^USD	+4.41%		-6.25%	+18.42%

05-08	Transcript : PolyPid Ltd., Q1 2024 Earnings Call, May 08, 2024
05-08	PolyPid Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

PolyPid Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022

February 08, 2023 at 07:15 am

PolyPid Ltd. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 39.53 million compared to USD 42.6 million a year ago. Basic loss per share from continuing operations was USD 60.9001 compared to USD 68.4001 a year ago.

Latest news about PolyPid Ltd.

Transcript : PolyPid Ltd., Q1 2024 Earnings Call, May 08, 2024	05-08
PolyPid Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
PolyPid Ltd. Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections	04-30	CI
Transcript : PolyPid Ltd., Q4 2023 Earnings Call, Feb 14, 2024	02-14
PolyPid Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-14	CI
PolyPid Ltd. Announces Enrollment of the 100th Patient in the Ongoing Shield II Phase 3 Trial	02-12	CI
PolyPid Ltd. announced that it has received $35.01012 million in funding from Dafna Capital Management, LLC, Rosalind Advisors, Inc.	01-21	CI
PolyPid Enters Into $16.2 Million Private Placement Deal	01-05	MT
PolyPid Ltd. announced that it expects to receive $16.216011 million in funding from Dafna Capital Management, LLC, Rosalind Advisors, Inc. and other investors	01-03	CI
Transcript : PolyPid Ltd., Q3 2023 Earnings Call, Nov 08, 2023	11-08
PolyPid Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-08	CI
Polypid Announces the Addition of Dr. Nurit Tweezer-Zaks to Its Board of Directors	11-07	CI
HC Wainwright Initiates PolyPid With Buy Rating, Price Target is $16	23-10-12	MT
Polypid Announces Publication of Preclinical Data Further Supporting the Good Safety Profile of D-Plex100 and Plex Technology Platform	23-10-04	CI
Top Premarket Decliners	23-09-27	MT
Top Premarket Decliners	23-09-26	MT
PolyPid Facility for D-PLEX100 Has no Critical Findings From Israeli Health Ministry Audit	23-09-21	MT
PolyPid to Implement 1-for-30 Reverse Stock Split	23-09-20	MT
PolyPid Completes Manufacturing-Process Validation for D-PLEX	23-09-19	DJ
PolyPid Ltd. Announces Successful Completion of Manufacturing Process Validation for D-PLEX100	23-09-19	CI
Transcript : PolyPid Ltd., Q2 2023 Earnings Call, Aug 09, 2023	23-08-09
PolyPid Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Polypid Ltd. Announces New Publication Highlighting Potent Antibacterial Activity of D-Plex Against Susceptible and Resistant Bacteria for the Prevention of Surgical Site Infections	23-06-29	CI
Certain Warrants of PolyPid Ltd. are subject to a Lock-Up Agreement Ending on 28-JUN-2023.	23-06-27	CI
Certain Options of PolyPid Ltd. are subject to a Lock-Up Agreement Ending on 28-JUN-2023.	23-06-27	CI

Chart PolyPid Ltd.

Duration

Period

More charts

Company Profile

Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.

Sector

Pharmaceuticals

Calendar

2024-05-13 - Citizens JMP Life Sciences Conference

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

4.31 USD

Average target price

12.33 USD

Spread / Average Target

+186.16%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
POLYPID LTD.	+18.42%	20.68M
ELI LILLY AND COMPANY	+32.77%	698B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.54%	358B
MERCK & CO., INC.	+19.16%	328B
ABBVIE INC.	+3.65%	283B
ASTRAZENECA PLC	+16.34%	238B
NOVARTIS AG	+6.68%	203B
ROCHE HOLDING AG	-9.08%	198B
AMGEN INC.	+8.50%	165B

Other Pharmaceuticals

PolyPid Ltd.

Equities

PYPD

IL0011326795

Pharmaceuticals

PolyPid Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022

Latest news about PolyPid Ltd.

Chart PolyPid Ltd.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals